Lupus & antiphospholipid syndrome
Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals With Autoimmune and Rheumatic Diseases
Authors' conclusion
CVEs were associated with modestly increased risks (20-70%) for PTB, SGA, or both across the groups.
Study context
- Population
- California population-based birth cohort (2005–2020) of pregnancies in individuals with autoimmune rheumatic diseases (ARDs), primary antiphospholipid syndrome (APS), or neither
- Participants
- 19,340 / 7,758 / 7,004,334
- Exposure
- Pregnancies with vs without maternal cardiovascular (CV) events, in ARD, primary APS and non-ARD/APS pregnancies
- ARDn = 19,340
- Primary APSn = 7,758
- Non-ARD/APSn = 7,004,334reference
- Outcome
- Adverse pregnancy outcomes (APOs): Preterm birth (PTB) (<37 weeks' gestation), SGA (birth weight <10th percentile for age and sex), and a composite of either outcome
Methodological detailsbirth cohort, ICD-9/10-CM codes in maternal discharge records
- Birth cohort
- ICD-9/10-CM codes in maternal discharge records
Main finding
As reported in the abstract
Incidence of adverse outcomes (CVEs present vs absent)
ARD: CV events (CVEs) present vs absent
53.2% vs 26.6%
APS: CVEs present vs absent
30.6% vs 20.7%
Non-ARD/APS: CVEs present vs absent
28.2% vs 15.2%
Observational data: associations, not effects.
Further findings
Frequency of CVEs
| Outcome | aRR (95% CI) | |
|---|---|---|
| PTB, CVEs vs no CVEsARD with CVEsvs ARD without CVEs | 1.6 (1.3–2.0) | |
| PTB, CVEs vs no CVEsNon-ARD/APS with CVEsvs Non-ARD/APS without CVEs | 1.7 (1.7–1.8) | |
| 0.512Adjusted relative risk (log scale) |
SGA, CVEs vs no CVEs
- Increased risk of SGA in all groups (adjusted risk ratios (aRRs))
- 1.2-1.5
Original publication
Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals With Autoimmune and Rheumatic Diseases. J Rheumatol. Published 15 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →